RHY Stock Overview
A medical diagnostics company, provides blood tests for the detection of cancers in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rhythm Biosciences Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.14 |
| 52 Week High | AU$0.19 |
| 52 Week Low | AU$0.042 |
| Beta | 2.42 |
| 11 Month Change | 27.27% |
| 3 Month Change | 118.75% |
| 1 Year Change | -22.22% |
| 33 Year Change | -92.45% |
| 5 Year Change | -3.45% |
| Change since IPO | -56.92% |
Recent News & Updates
Recent updates
Is Rhythm Biosciences (ASX:RHY) In A Good Position To Deliver On Growth Plans?
Dec 06
We're Not Very Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Rate
Aug 09We're Hopeful That Rhythm Biosciences (ASX:RHY) Will Use Its Cash Wisely
Apr 11Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation
Dec 02We're Hopeful That Rhythm Biosciences (ASX:RHY) Will Use Its Cash Wisely
Jul 19Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation
Mar 03Do Institutions Own Rhythm Biosciences Limited (ASX:RHY) Shares?
Dec 03Shareholder Returns
| RHY | AU Healthcare | AU Market | |
|---|---|---|---|
| 7D | 21.7% | 0.7% | 1.5% |
| 1Y | -22.2% | 4.0% | 17.2% |
Return vs Industry: RHY underperformed the Australian Healthcare industry which returned 4% over the past year.
Return vs Market: RHY underperformed the Australian Market which returned 17.2% over the past year.
Price Volatility
| RHY volatility | |
|---|---|
| RHY Average Weekly Movement | 18.2% |
| Healthcare Industry Average Movement | 5.1% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in AU Market | 17.3% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: RHY's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: RHY's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | David Atkins | rhythmbio.com |
Rhythm Biosciences Limited, a medical diagnostics company, provides blood tests for the detection of cancers in Australia. It develops ColoSTAT, a blood test for the early detection of colorectal cancer. Rhythm Biosciences Limited was incorporated in 2017 and is headquartered in Parkville, Australia.
Rhythm Biosciences Limited Fundamentals Summary
| RHY fundamental statistics | |
|---|---|
| Market cap | AU$32.32m |
| Earnings (TTM) | -AU$6.86m |
| Revenue (TTM) | AU$1.69m |
20.6x
P/S Ratio-5.1x
P/E RatioIs RHY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RHY income statement (TTM) | |
|---|---|
| Revenue | AU$1.69m |
| Cost of Revenue | AU$3.05m |
| Gross Profit | -AU$1.36m |
| Other Expenses | AU$5.50m |
| Earnings | -AU$6.86m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.028 |
| Gross Margin | -80.31% |
| Net Profit Margin | -405.69% |
| Debt/Equity Ratio | 0% |
How did RHY perform over the long term?
See historical performance and comparison